The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
399
OUTCOMES BY KEY PROGNOSTIC FACTORS IN EMERALD-1: A PHASE 3 STUDY OF DURVALUMAB ± BEVACIZUMAB WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PARTICIPANTS WITH EMBOLIZATION-ELIGIBLE UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)
Date
May 4, 2025
Explore related products in the following collection: